Lion's mane is one of the most hyped "brain mushrooms" on the supplement shelf. So what happens when healthy adults take a modest daily dose for a month and researchers measure both focus-related performance and blood levels of brain-derived neurotrophic factor (BDNF)?
A new pilot study in Nutrients tried to find out. The short version: nothing reached statistical significance. The longer version is more interesting, and more cautionary, than either the hype or a dismissal would suggest.
What the researchers did
The team, based largely at Nova Southeastern University with ties to the company Substantiation Sciences, enrolled 10 healthy adults aged 18 to 55. Each took 2 g per day of a certified organic Hericium erinaceus (lion's mane) supplement for 28 days. The product combined mycelial biomass and fruiting body.
Before and after the four weeks, participants completed two NIH Toolbox tests of executive function:
- Flanker Inhibitory Control and Attention Test, which measures how well you ignore distracting information and stay on task.
- Dimensional Change Card Sort (DCCS), which measures cognitive flexibility, or how well you switch rules.
Plasma BDNF was measured by ELISA. The researchers compared pre- and post-supplementation scores with paired t-tests and calculated Cohen's d effect sizes.
The results: no significant changes, small nudges
The headline finding is plain: no statistically significant differences (p > 0.05) in executive function or plasma BDNF after 28 days.
The effect sizes were small to moderate, in the direction of improvement:
| Measure | Cohen's d |
|---|---|
| Flanker inhibitory control/attention | 0.48 |
| DCCS (cognitive flexibility) | 0.25 |
| Plasma BDNF | 0.31 |
The authors describe these as "modest improvements from baseline" and a "promising signal." They also concluded that lion's mane was safe and well tolerated in this group.
How much weight can this bear?
Very little, and the design explains why.
It's tiny. With 10 people, a study is badly underpowered to detect modest effects. A non-significant result here doesn't show that lion's mane does nothing. It shows the study couldn't tell. The same applies in reverse: effect sizes from 10 people are unstable and can swing widely in a larger sample.
There's no placebo group. This was open-label, so everyone knew what they were taking. That leaves room for several non-supplement explanations for any small improvement:
- Practice effects: people often score better the second time they take a cognitive test.
- Expectation effects: people who believe a supplement will sharpen them may try harder.
- Normal day-to-day variation in attention, sleep, and stress.
The flanker result (d = 0.48) is the largest of the three, but it is exactly the kind of number a retest effect can produce.
BDNF is a tricky biomarker. Plasma BDNF is easy to measure but varies with time of day, exercise, stress, and sample handling. A change in the blood doesn't necessarily mean a change in the brain. A d of 0.31 that didn't reach significance is, at best, a hint worth testing properly.
Industry ties, disclosed
The conflict-of-interest statement notes that three authors were employed by Substantiation Sciences at the time of the study. Senior author Jose Antonio is CEO and co-founder of the International Society of Sports Nutrition, a non-profit that has received sponsorship from supplement companies, and he advises several brands. Disclosure is appropriate, and it isn't proof of bias. Still, it's one more reason to treat this as a hypothesis-generating pilot rather than evidence of benefit.
Practical takeaways
The dose studied. The study used 2 g per day for 28 days of a mycelium plus fruiting body blend. That is the only dose and form this particular study supports. It tells us nothing about higher doses, longer use, or other preparations.
Fruiting body vs. mycelium. This is the main product-picking issue in the category.
- Fruiting body is the actual mushroom. Products made from it typically list it explicitly, sometimes as an extract with a stated ratio.
- Mycelium is the root-like network, often grown on grain. Depending on the process, a "mycelium" product can contain substantial leftover substrate, so what you're buying may differ from what you assume.
- Because the compounds that get attention differ between the two parts, and research uses both, labels matter. Look for products that state which part is used, the amount per serving, and ideally third-party testing. Vague "proprietary blend" labels make it hard to compare your product with anything studied.
If you want to stay close to this study, a blend of both parts at about 2 g daily is the closest match, but the evidence doesn't show that blends beat either alone.
Realistic expectations. A month of lion's mane is unlikely to feel like a stimulant or a "limitless" effect. If this pilot's small signals are real at all, they're subtle and may not be noticeable day to day. Don't expect results from a bottle that you wouldn't expect from better-established habits like sleep, exercise, and managing stress.
Who might try it. Curious healthy adults who accept the uncertainty and want a low-risk experiment could reasonably consider it. If you try it:
- Change one thing at a time, so you can judge whether anything is different.
- Track something objective, such as a work log or a recurring cognitive task, rather than relying on how you feel.
- Give it the same four weeks the study used, then reassess.
Speak with a clinician first if you're pregnant or breastfeeding, take medications, have a mushroom allergy, or are using it to address a diagnosed cognitive problem. This study enrolled healthy adults only and can't speak to those situations.
The bottom line
The authors call the data a promising signal and ask for larger, longer, randomized, double-blind, placebo-controlled trials. That is the right framing. As it stands, 2 g a day of lion's mane for four weeks appeared safe in 10 healthy adults and produced small, non-significant shifts in attention, flexibility, and BDNF. Whether lion's mane sharpens focus or raises BDNF in any meaningful way remains an open question until a properly controlled trial answers it.